Skip to main content
SpringerLink
Log in

Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Specific antagonists of tumor necrosis factor (TNFα) have rapidly gain popularity for the treatment of ankylosing spondylitis (AS). The dose of etanercept has not been determined in Asia, especially in Korea. This study was designed to investigate the maintaining effect of low-dose (25 mg/week) etanercept in Korean patients with AS and after discontinuation, the duration to be aggravated. Patients who had active AS [Bath AS Disease Activity Index (BASDAI) ≥4] were treated with 50 mg of etanercept per week for 3 months. After that, for 6 months, the patients were treated with 25 mg of etanercept per week. We evaluated the serum erythrocyte sediment rate (ESR), C-reactive protein (CRP), and BASDAI every 1 month for 3 months and every 2–3 months during the remaining 6 months. After all schedules of treatment were finished, we reevaluated ESR, CRP, and BASDAI every 4 months until recurrence. Twenty-seven AS patients received etanercept. Twenty-three patients completed treatment for 3 months with a dose of 50 mg/week. Among them, 18 completed for 6 months with a dose of 25 mg/week and discontinued. Mean age was 30.0 ± 5.4 years and mean disease duration was 7.5 ± 6.5 years. These 18 patients were evaluated for BASDAI, ESR, and CRP every 4 weeks. After discontinuation, mean duration to recur was 9.2 ± 6.1 weeks. Twenty-five milligrams of etanercept per week is effective enough to maintain remission in AS. After discontinuation, this effect was maintained by using a dose of 50 mg of etanercept per week.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Malaviya AN, Mehra NK, Adhar G et al (1979) HLA B27 in patients with seronegative spondarthritides. J Rheumatol 6:413–416

    PubMed  CAS  Google Scholar 

  2. Mitsui H, Sonozaki H (1981) Ankylosing spondylitis in Japan. Ryumachi 21(Suppl):45–49

    PubMed  Google Scholar 

  3. Murata H, Inoue T (1993) Ankylosing spondylitis. Nippon Rinsho 51(Suppl):938–945

    PubMed  Google Scholar 

  4. Hukuda S, Minami M, Saito T et al (2001) Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 28:554–559

    PubMed  CAS  Google Scholar 

  5. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368

    Article  PubMed  Google Scholar 

  6. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291

    PubMed  CAS  Google Scholar 

  7. Schwartzman S, Morgan GJ Jr (2004) Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 6(Suppl 2):S19–S23

    Article  PubMed  CAS  Google Scholar 

  8. Genovese MC, Bathon JM, Fleischmann RM et al (2005) Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 32:1232–1242

    PubMed  CAS  Google Scholar 

  9. Moreland LW, Cohen SB, Baumgartner SW et al (2001) Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol 28:1238–1244

    PubMed  CAS  Google Scholar 

  10. Johnsen AK, Schiff MH, Mease PJ et al (2006) Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 33:659–664

    PubMed  CAS  Google Scholar 

  11. Jois RN, Leeder J, Gibb A et al (2006) Low-dose infliximab treatment for ankylosing spondylitis-clinically- and cost-effective. Rheumatology (Oxford) 45(12):1566–1569

    Article  CAS  Google Scholar 

  12. Brandt J, Khariouzov A, Listing J et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667–1675

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

I specially thank my patients who were enrolled in this study.

Author information

Authors and Affiliations

  1. Department of Rheumatology, College of Medicine, Kyunghee University, Seoul, South Korea

    Sang-Hoon Lee, Yeon-Ah Lee & Seung-Jae Hong

  2. Department of Rheumatology, Center of Arthritis and Rheumatism, East West Neo-Medical Center of Kyung Hee University, 149, Sangil-dong, Gangdong-gu, Seoul, 134-090, South Korea

    Hyung-In Yang

Authors
  1. Sang-Hoon Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yeon-Ah Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seung-Jae Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyung-In Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyung-In Yang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, SH., Lee, YA., Hong, SJ. et al. Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 27, 179–181 (2008). https://doi.org/10.1007/s10067-007-0674-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-007-0674-2

Keywords

Search

Navigation